Enanta Pharmaceuticals, Inc. (ENTA)
Develops experimental antiviral drugs to treat hepatitis, respiratory viruses, and immune disorders.
$12.61-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+77.4%
The outlook
ENTA is trading below both its 50- and 200-day moving averages, sitting in the middle of its 52-week range. Analyst coverage shows an average price target about 68% above the current price, though the overall StockGlow score remains neutral at 43/100.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range58% of the way from its 52-week low to high
Price targetAvg target +68% vs current price
Analyst price target
~12-month · 6 analysts$21.17average target+67.9% vs now
Now $12.61
Low $19.00High $28.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$366.7M
52-wk high
$17.15
52-wk low
$6.45
50-day avg
$13.16
200-day avg
$13.28
Trailing P/E
—